EATG » Hepatitis

Hepatitis

Study explores marijuana use and fibrosis in women with HIV and hepatitis C

A study in women coinfected with hepatitis C and HIV found that use of marijuana was not associated with progression to advanced liver fibrosis. University researchers studied long-term effects of…

Alliance announced hepatitis C testing results in Ukraine

Hepatitis C – “Frozen War” with an Invisible Enemy. Results of the national testing. On 10 August 2016, Alliance for Public Health (Alliance) during its press briefing in the Ukrainian…

HCV drug effective in patients with drug addiction

The combination drug elbasvir/grazoprevir (Zepatier, Merck) reduced viral load in patients with chronic hepatitis C virus (HCV) infection being treated for opioid addiction in a randomized controlled trial. The favorable…

Why are hepatitis C patients treated differently by NHS England?

NHS England’s decision to cap access to National Institute for Health and Care Excellence (NICE) approved hepatitis C treatments has been attributed to their cost. These antiviral medicines have led…

Long-term lamivudine therapy leads to HBsAg loss in patients with HBV

Long-term lamivudine therapy led to hepatitis B surface antigen loss in patients with chronic hepatitis B, according to recent findings published in Alimentary Pharmacology & Therapeutics. “Lamivudine was found to…

Hepatitis is on the rise as a global killer

More people are dying from viral liver disease than ever before, scientists have found. While much progress has been made to curb the spread of infectious diseases like HIV, TB…

HCV RNA persists in liver after interferon-free treatment regimens

Hepatitis C virus (HCV) RNA persists in two-thirds of liver explants from patients who were treated with interferon-free regimens, researchers report. Patients awaiting liver transplant receive antiviral treatment to eradicate…

Risk score accurately predicts acute HCV risk in MSM with HIV

Researchers from the Netherlands developed a new risk score that accurately predicted the risk for acute HCV infection in men with HIV who have sex with men, according to an…

Inovio will independently develop hepatitis B immunotherapy

PLYMOUTH MEETING, Pa., Aug. 03, 2016 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the company will continue to develop its hepatitis B DNA immunotherapy (INO-1800) independently following Roche’s notice that…

Sofosbuvir-ribavirin works against HCV genotype 2 in real-world

The combination of sofosbuvir and ribavirin is effective for treating hepatitis C virus (HCV) genotype 2 in real-world, clinical practice, the HCV-TARGET study confirms. The combination is currently recommended for…